LifeStance Health Group, Inc. (NASDAQ:LFST) Receives $8.25 Average Target Price from Analysts

LifeStance Health Group, Inc. (NASDAQ:LFST) has been assigned a consensus rating of “Hold” from the six research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $8.25.

Several research analysts have issued reports on the company. Barclays dropped their price objective on LifeStance Health Group from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Friday, August 9th. UBS Group decreased their target price on LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating on the stock in a report on Thursday, August 15th.

Insiders Place Their Bets

In other news, insider Ann Varanakis sold 5,269 shares of LifeStance Health Group stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $6.28, for a total transaction of $33,089.32. Following the completion of the sale, the insider now owns 263,007 shares in the company, valued at approximately $1,651,683.96. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 6.60% of the company’s stock.

Institutional Trading of LifeStance Health Group

A number of institutional investors have recently bought and sold shares of the business. Bessemer Group Inc. boosted its position in shares of LifeStance Health Group by 43.4% in the 1st quarter. Bessemer Group Inc. now owns 9,143 shares of the company’s stock worth $56,000 after purchasing an additional 2,768 shares during the last quarter. CIBC Asset Management Inc bought a new position in LifeStance Health Group during the second quarter worth about $53,000. Algert Global LLC acquired a new position in shares of LifeStance Health Group during the 2nd quarter worth about $57,000. Assetmark Inc. increased its stake in shares of LifeStance Health Group by 21.6% in the 4th quarter. Assetmark Inc. now owns 11,895 shares of the company’s stock valued at $93,000 after acquiring an additional 2,114 shares during the last quarter. Finally, Allen Investment Management LLC acquired a new stake in shares of LifeStance Health Group in the 1st quarter valued at approximately $79,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $6.94 on Monday. LifeStance Health Group has a twelve month low of $4.64 and a twelve month high of $9.20. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 0.20. The stock has a market cap of $2.65 billion, a P/E ratio of -14.46 and a beta of 1.22. The company’s 50-day simple moving average is $5.90 and its 200 day simple moving average is $6.05.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $312.30 million for the quarter, compared to analyst estimates of $305.85 million. LifeStance Health Group had a negative return on equity of 10.51% and a negative net margin of 13.05%. The company’s revenue was up 20.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.13) EPS. As a group, research analysts forecast that LifeStance Health Group will post -0.24 earnings per share for the current fiscal year.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.